Reduction of Sudden Deaths After Myocardial Infarction

Ahlmark, Gösta; Saetre, H; Korsgren, Magnus

doi:10.1016/s0140-6736(74)90299-2

Cited by 135 publications

(20 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overall trials of ,3-adrenoceptor blocking drugs post-infarction indicate the drugs produce benefit (Baber & Lewis, 1982;Hampton, 1982;Lancet, 1982;Rose, 1982;Turi & Braunwald, 1983), although like all drugs, there is a benefit risk ratio (Breckenridge, 1982). A number of the studies can be criticized on methodological grounds (Fitzgerald, 1976;Hampton, 1981) and there have been some negative results (Baber et al, 1980;Wilcox etal., 1980) but there have now been numerous reports that indicate ,B-adrenoceptor blocking drugs are effective in reducing the recurrence rate of myocardial infarction (Ahlmark et al, 1974;Wilhelmsen et al, 1973;Multicentre International Study, 1975;Hjalmarson et al, 1981;Norwegian Multicenter Study Group, 1981;BHAT 1982;Hansteen et al, 1982;Julian et al, 1982). This evidence and that for there being an effect in acute myocardial infarction suggests that there is a cardioprotective effect in high risk patients following myocardial infarction.…”

Section: /3-adrenoceptor Blocking Drugsmentioning

confidence: 99%

The management of hypertension.

Prichard¹,

Owens²

1986

Brit J Clinical Pharma

View full text Add to dashboard Cite

Section: /3-adrenoceptor Blocking Drugsmentioning

confidence: 99%

The management of hypertension.

Prichard¹,

Owens²

1986

Brit J Clinical Pharma

View full text Add to dashboard Cite

“…Although a number of the studies can be criticised on methodological grounds (Fitzgerald, 1976), investigations in post-infarction patients have sug gested that there is a reduction in recurrence of myocardial infarction and/or sudden death in those patients given (3-adrenergic-blocking drugs (Wilhelmsson et al, 1974;Ahlmark et al, 1974;Multicentre Trial, 1975). A similar effect has been observed in patients with angina pectoris (Lambert, 1976).…”

Section: Long-term Cardioprotective Effectmentioning

confidence: 99%

<i>β</i>-Adrenoceptor-Blocking Agents in the Management of Hypertension

Prichard

1979

Cardiology

View full text Add to dashboard Cite

“…Patients were selected for study only if control ambulatory electrocardiographic monitoring showed more than one PVC per minute averaged over 24 The magnetic tapes containing 24 hours of ambulatory electrocardiographic recording were processed using a previously described computer-based system16 17 in which PVCs are quantitated over the entire 24-hour period, and the data are expressed as PVCs per 15-minute segment (PVCs/15'). The accuracy of the quantitation is checked by sampling one representative segment of electrocardiographic signal each half hour over the duration of the recording.…”

Section: Patient Populationmentioning

confidence: 99%

Suppression of premature ventricular contractions by acebutolol.

Gradman¹,

Winkle²,

Fitzgerald³

et al. 1977

Circulation

View full text Add to dashboard Cite

SUMMARY The antiarrhythmic action of the beta-blocking drug, acebutolol, was evaluated in patients with frequent premature ventricular contractions (PVCs). In the 12 hours following administration of a single 300 mg oral dose, 8 of 10 patients showed a greater than 50% reduction in PVC frequency, and statistical analysis indicated that PVC reduction persisted for 10 hours after the single dose. Analysis of plasma concentrations of acebutolol and an acetyl metabolite indicated that after single oral doses the plasma concentrations of the metabolite exceed those of unchanged acebutolol.A POSITIVE CORRELATION between the presence of frequent premature ventricular contractions (PVCs) and the subsequent incidence of sudden cardiac death has been observed,1' 2 particularly in patients with coronary artery disease.8 3 It is a reasonable though unproven hypothesis that suppression of these ectopic impulses would result in a decrease in the incidence of sudden death in these patients. Testing of this hypothesis has been limited to date primarily by the lack of antiarrhythmic drugs suitable for chronic administration.6 7 Such drugs should be effective, free of toxicity, and have properties that allow administration on a convenient dosage schedule which permits patient compliance. The development of such agents is currently the goal of extensive laboratory and clinical investigation.Acebutolol, (M&B 17803A) (±)-1-(2-acetyl-4-n-butyramido-phenoxy)-2-hydroxy-3-isopropylaminopropane ( fig. 1) is a new, relatively cardioselective beta-adrenergic antagonist. Acebutolol blocks the myocardial beta-receptors by a competitive inhibition and has a weak sympathomimetic action.8 In intravenous studies, it has approximately one-seventh the beta-blocking potency of propranolol.9 In addition, it has the membrane-stabilizing, so-called "quinidine-like" property found in propranolol but not in practolol.'0 In experimental arrhythmia studies, differences from both propranolol and practolol have been noted1' which have potential clinical utility, and preliminary clinical arrhythmia studies are promising.'2 The drug has less effect on the beta-receptors of bronchial smooth muscle than propranolol and has been administered to asthmatics.'8 Acebutolol has also been used successfully in When patients were studied during periods of 300 mg doses every 8 hours, eight of 11 showed a 70% reduction in PVC frequency, and analysis showed that the therapeutic effect was present throughout the 24-hour monitoring period. Acebutolol slowed the heart rate and prolonged the PR interval without affecting the QT interval. Significant clinical or laboratory toxicity was not encountered. In the small group studied, acebutolol was found to be safe and effective for shortterm administration to patients with frequent PVCs and possessed a relatively long duration of antiarrhythmic action.of acebutolol to a group of ambulatory patients with frequent PVCs. Methods Patient PopulationTwelve patients, 11 men and one woman, participated in the study after giving written...

show abstract

Reduction of Sudden Deaths After Myocardial Infarction

Cited by 135 publications

References 0 publications

The management of hypertension.

The management of hypertension.

<i>β</i>-Adrenoceptor-Blocking Agents in the Management of Hypertension

Suppression of premature ventricular contractions by acebutolol.

Contact Info

Product

Resources

About

Reduction of Sudden Deaths After Myocardial Infarction

Cited by 135 publications

References 0 publications

The management of hypertension.

The management of hypertension.

<i>&beta;</i>-Adrenoceptor-Blocking Agents in the Management of Hypertension

Suppression of premature ventricular contractions by acebutolol.

Contact Info

Product

Resources

About

<i>β</i>-Adrenoceptor-Blocking Agents in the Management of Hypertension